September 14, 2020 09:37 AM EDTUpdated 10:51 AM

Here's a look at everything Merck's BD group has done in the past 12 years, illustrating why the Seattle Genetics deal stands out

John Carroll

Editor & Founder

A little over 3 years ago, Merck splashed into a licensing deal with AstraZeneca covering their blockbuster Lynparza franchise with $1.6 billion in cash upfront …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Here's a look at everything Merck's BD group has done in the past 12 years, illustrating why the Seattle Genetics deal stands out

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Here's a look at every­thing Mer­ck­'s BD group has done in the past 12 years, il­lus­trat­ing why the Seat­tle Ge­net­ics deal stands out

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Here's a look at everything Merck's BD group has done in the past 12 years, illustrating why the Seattle Genetics deal stands out

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway